Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Add To Watchlist

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire April 30, 2024

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

PR Newswire April 25, 2024

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

PR Newswire April 11, 2024

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

PR Newswire April 2, 2024

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

PR Newswire March 7, 2024

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Newsfile March 6, 2024

Oncolytics Biotech to initiate new pancreatic cancer therapy study

Jonathon Brown March 5, 2024

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

PR Newswire March 5, 2024

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

PR Newswire March 4, 2024

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

PR Newswire February 28, 2024

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Newsfile February 15, 2024

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

PR Newswire February 14, 2024

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

PR Newswire January 9, 2024

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

PR Newswire January 4, 2024

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

PR Newswire December 7, 2023

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

PR Newswire November 9, 2023

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

PR Newswire November 9, 2023

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

PR Newswire November 3, 2023

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

PR Newswire November 3, 2023

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

PR Newswire October 23, 2023